RedditBluesky
  • Home
  • Artificial Intelligence
  • Cryptocurrencies
  • Technology
  • Gold
  • Stocks
Home » News » What Are The Health Benefits And Risks Of Marijuana?

What Are The Health Benefits And Risks Of Marijuana?

This is what science says

Justin Wong (JW)October 5, 2026



According to the National Institutes of Health, people have been using marijuana or cannabis to treat their ailments for at least 3,000 years. However, the Food and Drug Administration has not classified marijuana as safe or effective for treating disease, although cannabidiol, a substance found in marijuana, was approved as a treatment for some types of epilepsy in June 2018.

This tension between the widespread belief that marijuana is an effective treatment for a wide range of diseases and the lack of scientific knowledge about its effects has been exacerbated somewhat in recent times by the drive towards legalization.

Twenty-nine states and the District of Columbia have now approved marijuana for medical use, and in some states for recreational use as well.

A recent study published in the journal Addiction, Trusted Source, also found that marijuana use is increasing sharply in the United States, although that increase is not necessarily related to the legalization of marijuana in participating states. Nonetheless, this increase in consumption gives cause for great public health concern.

In this article, we delve into the scientific evidence that weighs the medicinal benefits of marijuana against the health risks associated with it to find an answer to the simple question: is marijuana good or bad?

What are the Medical Benefits of Marijuana? Over the years research has produced results that suggest that marijuana may be of benefit in treating some diseases. These are listed below.

Chronic pain Last year, an extensive report from the National Academies of Sciences, Engineering, and Medicine evaluated more than 10,000 scientific studies of the medical benefits and negative effects of marijuana.

One area that the report carefully examined was the use of medical marijuana to treat chronic pain. Chronic pain is a leading cause of disability affecting more than 25 million adults in the US Trusted Source

The research found that marijuana, or products containing cannabinoids - the active ingredients in marijuana - or other compounds that act on the same receptors in the brain as marijuana, were effective for chronic pain.

Alcoholism and drug addiction Another in-depth research published in the Clinical Psychology Review last year found that marijuana use can help people with alcohol or opioid addictions fight their addiction.

However, this result is controversial; the National Academies of Sciences review suggests that marijuana use actually increases the risk of abusing and becoming dependent on other substances.

The more often someone uses marijuana, the more likely they are to develop a problem with marijuana use. It is also known that individuals who started using the drug at a young age have an increased risk of developing a problem with marijuana use.

Depression, Post Traumatic Stress Disorder, and Social Anxiety The review, published in the journal Clinical Psychology Review, evaluated all published scientific literature examining the use of marijuana to treat symptoms of mental illness.

The authors found some evidence of the use of marijuana for relief from depression and post-traumatic stress disorder.

However, they point out that marijuana is not an appropriate treatment for some other mental illnesses, such as bipolar disorder and psychosis.

The report suggests that there is some evidence to suggest that marijuana might relieve symptoms of social anxiety, but again contradicts the report from the National Academies of Sciences, Engineering, and Medicine, which instead states that regular marijuana users are one have an increased risk of social anxiety.

cancer There is evidence that cannabinoids taken orally are effective for nausea and vomiting caused by chemotherapy, and some small studies have found that smoked marijuana can also help relieve these symptoms, familiar source.

Some studies on cancer cells suggest that cannabinoids can either slow the growth of some cancers or kill them. However, early studies testing this hypothesis in humans showed that cannabinoids, while safe treatment, are not effective at controlling or curing cancer.

multiple sclerosis Short-term use of oral cannabinoids can improve symptoms of spasticity in people with multiple sclerosis, but the positive effects have been rated as modest.

epilepsy In June 2018, the Food and Drug Administration (FDA) approved the use of a drug containing cannabidiol (CBD) to treat two rare, severe, and specific types of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, that are difficult to control with other types of medication. This CBD-based drug is known as Epidiolex.

CBD is one of the many substances found in cannabis. It's not psychoactive. The drug used to treat these conditions is a purified form of CBD. Approval is based on the results of research and clinical studies.

A study published in 2017 found that using CBD in children with Dravet syndrome resulted in significantly fewer seizures compared to a placebo.

Seizures in Dravet syndrome are long, repetitive, and potentially fatal. In fact, 1 in 5 children with Dravet syndrome will not reach the age of 20.

In the study, 120 children and adolescents with Dravet syndrome, ages 2-18 years old, were randomly assigned to an oral CBD solution or placebo, which they received with their usual medication for 14 weeks.

The researchers found that among the children who received the CBD solution, the number of seizures decreased from around 12 per month to an average of six per month. Three children who received CBD had no more seizures at all.

The number of seizures also decreased in the children who received the placebo, but only slightly - the average number of seizures decreased from 15 per month before the study to 14 per month during the study.

The researchers say this 39 percent reduction in the occurrence of seizures is strong evidence that the drug can help people with Dravet syndrome, and that their study provides the first rigorous scientific data to support it.

However, the study also found a high rate of side effects related to CBD. More than 9 out of 10 children treated with CBD experienced side effects - the most common being vomiting, fatigue, and fever.

The Epidiolex package insert warns of side effects such as liver damage, sedation, and thoughts of suicide.

What are the health risks of marijuana? At the other end of the spectrum, there is an abundance of studies that have found negative associations between marijuana use and health. They are listed below.

Mental health problems Daily marijuana use is believed to worsen existing symptoms of bipolar disorder in people with this mental health problem. However, the report from the National Academies of Sciences, Engineering, and Medicine suggests that there is limited evidence of an association between marijuana use and the development of bipolar disorder in people with no history.

Moderate evidence suggests that regular marijuana users are more likely to be suicidal, and there is a slightly increased risk of depression among marijuana users.

Marijuana use likely increases your risk of developing psychosis, including schizophrenia. However, a curious finding in people with schizophrenia and other psychoses is that previous marijuana use is linked to better performance on learning and memory tests.

Testicular cancer While there is no evidence of an association between marijuana use and an increased risk of most cancers, the National Academies of Sciences found some evidence of increased risk for the slow-growing seminoma subtype of testicular cancer.

Respiratory diseases Regular marijuana smoking has been linked to an increased risk of chronic cough, but it is "unclear" whether smoking marijuana worsens lung function or increases the risk of chronic obstructive pulmonary disease or asthma.

A 2014 study examining the link between marijuana use and lung disease suggests that it is plausible that smoking marijuana could contribute to lung cancer, although it was difficult to establish a clear link between the two.

The authors of this study, published in the journal Current Opinion in Pulmonary Medicine, conclude:

"There is strong evidence that habitual or regular marijuana smoking is not harmless. A warning against regular heavy marijuana use is appropriate."

"The medicinal use of marijuana in low cumulative doses is unlikely to be harmful to the lungs," they add, "but the dose limit needs to be defined. Recreational use is not the same as medicinal use and should not be recommended.

So is marijuana good or bad for your health? There is evidence to show both the harms and health benefits of marijuana. Yet, although very comprehensive, up-to-date reviews of the scientific studies evaluating the drug's benefits and harms have appeared in recent years, it is clear that more research is needed to fully determine the public health effects of increasing marijuana use.

Many scientists and health organizations - including the American Cancer Society Trusted Source (ACS) - support the need for more scientific research into the use of marijuana and cannabinoids to treat disease.

However, there is an obstacle to this: marijuana is classified by the Drug Enforcement Administration as a List I controlled substance, which impairs research into marijuana and cannabinoids by imposing strict requirements on researchers working in this field.

If you live in a state where the medical use of marijuana is legal, you and your doctor must carefully weigh these factors and their relationship to your illness and health history before using this drug.

While there is some evidence of using marijuana for pain relief, you should definitely avoid marijuana if you have a history of mental health problems.

Remember to always speak to your doctor before starting any new medication.

CannabisForschung





Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.


Claw and Order: Antimony Rules the Resource Realm
Read Next

Claw and Order: Antimony Rules the Resource Realm

  • RIDE THE BULL

    Your Front Row Seat to the Stories That Move Markets. – Subscribe Now to our Newsletter!

  • Trending Now

    • Mark Carney Single-Outs NexGen's Rook 1 as a Critical Project of National Interest
      Mark Carney Single-Outs NexGen's Rook 1 as a Critical Project of National Interest
    • Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
      Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
    • Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
      Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
    • Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama
      Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama

Claim Your Spot with Juniorstocks.com

Unlock the stories that move markets directly in your inbox


ContactDisclaimerData PrivacyTerms of Use
  • Bluesky
  • Reddit
Copyright 2026 ©Juniorstocks.com - All Rights Reserved.